Commodore Capital LP: CELLDEX THERAPEUTICS INC (CLDX): Quarterly 13F Position History
As of Q1 2026, Commodore Capital LP reported 2,696,616 shares of CELLDEX THERAPEUTICS INC (CLDX), worth $85.5M and representing 4.9% of its 13F equity book. Quarter-over-quarter share count change: + 131,616 (+5.1%) . The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 2,696,616Shares Held (Latest Filing)
- $85.5MReported Market Value (Latest Filing)
- 4.9%Portfolio Weight (% of 13F Equity Book)
- +131,616Quarter-over-Quarter Share Change
- +$15.9MQuarter-over-Quarter Value Change
- 3,450,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,696,616 | +131,616 | +5.1% | $85.5M | 4.9% | $31.7 |
| Q4 2025 | 2,565,000 | 463,335 | -15.3% | $69.7M | 4.6% | $27.2 |
| Q3 2025 | 3,028,335 | 421,665 | -12.2% | $78.3M | 3.8% | $25.9 |
| Q2 2025 | 3,450,000 | +250,000 | +7.8% | $70.2M | 5.0% | $20.4 |
| Q1 2025 | 3,200,000 | +3,200,000 | — | $58.1M | 4.3% | $18.1 |
| Q4 2024 | 0 | 1,618,937 | -100.0% | $0 | 0.0% | — |
| Q3 2024 | 1,618,937 | +193,937 | +13.6% | $55.0M | 3.4% | $34.0 |
| Q2 2024 | 1,425,000 | +558,532 | +64.5% | $52.7M | 3.6% | $37.0 |
| Q1 2024 | 866,468 | +164,501 | +23.4% | $36.4M | 2.4% | $42.0 |
| Q4 2023 | 701,967 | 4,698 | -0.7% | $27.8M | 2.4% | $39.7 |
| Q3 2023 | 706,665 | +75,000 | +11.9% | $19.4M | 2.3% | $27.5 |
| Q2 2023 | 631,665 | +135,842 | +27.4% | $21.4M | 2.4% | $33.9 |
| Q1 2023 | 495,823 | 0 | — | $17.8M | 2.7% | $36.0 |
| Q4 2022 | 495,823 | 42,989 | -8.0% | $22.1M | 3.3% | $44.6 |
| Q3 2022 | 538,812 | 0 | — | $15.1M | 2.4% | $28.1 |
| Q2 2022 | 538,812 | +297,613 | +123.4% | $14.5M | 3.1% | $27.0 |
| Q1 2022 | 241,199 | +241,199 | — | $8.2M | 1.8% | $34.1 |
| Q4 2021 | 0 | 248,207 | -100.0% | $0 | 0.0% | — |
| Q3 2021 | 248,207 | 75,230 | -23.3% | $13.4M | 3.5% | $54.0 |
| Q2 2021 | 323,437 | 46,514 | -12.6% | $10.8M | 3.7% | $33.4 |
| Q1 2021 | 369,951 | +13,520 | +3.8% | $7.6M | 3.0% | $20.6 |
| Q4 2020 | 356,431 | — | — | $6.2M | 3.4% | $17.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Commodore Capital LP first disclose a CLDX position in 13F-HR filings?
Commodore Capital LP first reported CELLDEX THERAPEUTICS INC (CLDX) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Commodore Capital LP's most recent quarter-over-quarter share-count change in CLDX?
Between Q4 2025 and Q1 2026, Commodore Capital LP added 131,616 shares of CLDX (+5.1%), bringing the total reported position to 2,696,616 shares at a market value of $85.5M.
Does the implied price-per-share represent Commodore Capital LP's cost basis in CLDX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.